Business 4 min read By Alice Ashford
Elekta margins surge but revenue growth lags market in Q1 FY27
Elekta's first-quarter results show a sharp improvement in margins, but revenue growth has not kept pace with market expectations, raising questions about the company's near-term sales momentum.
Elekta, the Swedish medical technology group, has reported a significant surge in margins for the first quarter of its 2027 fiscal year, although revenue growth has fallen short of broader market performance. The results, presented in the company's Q1 FY27 slides, indicate that profitability improvements are outpacing top-line expansion, a divergence that investors are likely to scrutinise closely.
The company, which specialises in precision radiation therapy and oncology solutions, has been navigating a competitive landscape where demand for its equipment and software remains steady but pricing pressure and market saturation in certain regions continue to weigh on sales growth. While the margin uplift suggests operational efficiencies and cost discipline are taking effect, the slower revenue trajectory points to challenges in converting pipeline opportunities into confirmed orders.
Market analysts have noted that Elekta's growth rate is lagging behind the wider medical technology sector, which has benefited from renewed hospital capital expenditure cycles and technological upgrades. The company's focus on expanding its installed base and recurring service revenue has provided some stability, but the pace of new system sales has not matched the optimism seen in competitor forecasts.
The margin improvement is partly attributed to a favourable product mix and supply chain stabilisation, which have reduced manufacturing costs and improved delivery timelines. Elekta has also streamlined its portfolio, prioritising higher-margin software and digital solutions over legacy hardware, a strategy that appears to be paying off in profitability terms even if it has yet to translate into accelerated revenue growth.
Investor reaction to the quarterly update has been cautious, with the stock reflecting the mixed signals from the results. The company's guidance for the full year remains unchanged, suggesting management expects the current trajectory to persist. However, the gap between margin performance and revenue expansion raises questions about whether Elekta can sustain its profitability gains without a corresponding pickup in sales momentum.
Elekta's leadership has emphasised that the focus on margin enhancement is deliberate, aimed at building a more resilient business model that can withstand market volatility. The company continues to invest in research and development, particularly in AI-driven treatment planning and adaptive radiotherapy, areas where it sees long-term growth potential. These investments, while necessary, are also contributing to the near-term divergence between profit and revenue performance.
Looking ahead, Elekta faces the dual challenge of maintaining its margin trajectory while reigniting revenue growth. The company's ability to secure large-scale contracts in emerging markets and expand its digital health offerings will be critical to closing the gap. For now, the Q1 results present a picture of a company that is financially healthier but commercially more cautious than its market peers.
